UB Paderborn / Katalog / Suche / in CDI

Precision partial scapular bone sarcoma resections and functional reconstructions with 3D printed Patient-Specific implants: Cases report

Annals of 3D printed medicine, 2023-05, Vol.10, p.100105, Article 100105

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

BMJ open respiratory research, 2023-07, Vol.10 (1), p.e001627

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B

Journal of hepatology, 2018-03, Vol.68 (3), p.431-440

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

The European respiratory journal, 2021-10, Vol.58 (4), p.2100673

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn’s Disease

Inflammatory bowel diseases, 2022-08, Vol.28 (8), p.1207-1218

2022

Link zum Volltext

Verfügbarkeit prüfen

Tu1880 EFFECTS OF THE JANUS KINASE (JAK1)-SELECTIVE INHIBITOR FILGOTINIB (FIL) ON CIRCULATING CYTOKINES AND WHOLE-BLOOD GENES/PATHWAYS OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD)

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1201-S-1202

2020

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Blood, 2022-11, Vol.140 (Supplement 1), p.5961-5962

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme

Journal of Crohn's and colitis, 2020-09, Vol.14 (9), p.1202-1213

2020

Link zum Volltext

Verfügbarkeit prüfen

TD-8236, a lung-selective inhaled pan-JAK inhibitor, inhibits gene expression related to severe asthma and exhaled nitric oxide (FeNO), in 3-D airway epithelium liquid interface (ALI) cultures derived from asthmatic donors

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB116

2020

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Tumor Necrosis Factor mRNA Translation by a Rationally Designed Immunomodulatory Peptide

The Journal of biological chemistry, 2000-06, Vol.275 (22), p.17051-17057

2000

Link zum Volltext

Verfügbarkeit prüfen

Sa1757 - Filgotinib Decreases Systemic and Mucosal Markers of Inflammation that are Associated with Endoscopic Improvement in Moderatly to Severely Active Crohn's Disease Patients

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-383-S-383

2018

Link zum Volltext

Verfügbarkeit prüfen

Stress protein-induced immunosuppression: inhibition of cellular immune effector functions following overexpression of haem oxygenase (HSP 32)

Transplant immunology, 1998-06, Vol.6 (2), p.84-93

1998

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects

Antiviral therapy, 2020-01, Vol.25 (3), p.171-180

2020

Link zum Volltext

Verfügbarkeit prüfen

Tu1980 Correlation of Mucosal MMP9 Expression with Mayo Score and Endoscopic Sub-Score in Patients with Moderately to Severely Active Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S996-S996

2016

Link zum Volltext

Verfügbarkeit prüfen

Tu1982 MMP9 Catalytic Activity Is Elevated in Colon Tissue of Patients with IBD

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S996-S997

2016

Link zum Volltext

Verfügbarkeit prüfen

Development of a quantitative immunofluorescent method for analysis of nuclear and cytoplasmic p53 and p21 in circulating tumor cells (CTC) as biomarkers of response to p53-targeted therapy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13575-e13575

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2381: ApoStreamtm, an antibody independent platform, captures circulating tumor cells in patients with hepatocellular carcinoma

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2381-2381

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic monitoring of DNA damage biomarkers in circulating tumor cells (CTCs) to assess the mechanism of action of the topoisomerase-1 (Topo1) inhibitor, NKTR-102

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13577-e13577

2012

Link zum Volltext

Verfügbarkeit prüfen

Antibody-independent ApoStream technology isolates folate receptor alpha (FRA)–positive circulating tumor cells from blood of non-small cell lung adenocarcinoma patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e21028-e21028

2012

Link zum Volltext

Verfügbarkeit prüfen

ApoStream, a novel device for antibody-independent capture of circulating cancercells (CCCs) from blood of patients with various types of cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13500-e13500

2012

Link zum Volltext

Verfügbarkeit prüfen

ApoStream, an antibody-independent platform, compared to CellSearch for enumeration of circulating tumor cells (CTCs) in patients with metastatic prostate cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e21058-e21058

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3159: BRAFV600E mutation analysis in circulating tumor cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3159-3159

2011

Link zum Volltext

Verfügbarkeit prüfen

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis

Arthritis research & therapy, 2013-01, Vol.15 (6), p.R207-R207

2013

Link zum Volltext

Verfügbarkeit prüfen

Expression of eIF4E relevant biomarkers detected in circulating tumor cells from metastatic NSCLC and prostate cancer patients using antibody-independent ApoStream technology

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13562-e13562

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Precision partial scapular bone sarcoma resections and functional reconstructions with 3D printed Patient-Specific implants: Cases report

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn’s Disease

Tu1880 EFFECTS OF THE JANUS KINASE (JAK1)-SELECTIVE INHIBITOR FILGOTINIB (FIL) ON CIRCULATING CYTOKINES AND WHOLE-BLOOD GENES/PATHWAYS OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD)

Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme

TD-8236, a lung-selective inhaled pan-JAK inhibitor, inhibits gene expression related to severe asthma and exhaled nitric oxide (FeNO), in 3-D airway epithelium liquid interface (ALI) cultures derived from asthmatic donors

Inhibition of Tumor Necrosis Factor mRNA Translation by a Rationally Designed Immunomodulatory Peptide

Sa1757 - Filgotinib Decreases Systemic and Mucosal Markers of Inflammation that are Associated with Endoscopic Improvement in Moderatly to Severely Active Crohn's Disease Patients

Stress protein-induced immunosuppression: inhibition of cellular immune effector functions following overexpression of haem oxygenase (HSP 32)

Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects

Tu1980 Correlation of Mucosal MMP9 Expression with Mayo Score and Endoscopic Sub-Score in Patients with Moderately to Severely Active Ulcerative Colitis

Tu1982 MMP9 Catalytic Activity Is Elevated in Colon Tissue of Patients with IBD

Development of a quantitative immunofluorescent method for analysis of nuclear and cytoplasmic p53 and p21 in circulating tumor cells (CTC) as biomarkers of response to p53-targeted therapy

Abstract 2381: ApoStreamtm, an antibody independent platform, captures circulating tumor cells in patients with hepatocellular carcinoma

Pharmacodynamic monitoring of DNA damage biomarkers in circulating tumor cells (CTCs) to assess the mechanism of action of the topoisomerase-1 (Topo1) inhibitor, NKTR-102

Antibody-independent ApoStream technology isolates folate receptor alpha (FRA)–positive circulating tumor cells from blood of non-small cell lung adenocarcinoma patients

ApoStream, a novel device for antibody-independent capture of circulating cancercells (CCCs) from blood of patients with various types of cancer

ApoStream, an antibody-independent platform, compared to CellSearch for enumeration of circulating tumor cells (CTCs) in patients with metastatic prostate cancer

Abstract 3159: BRAFV600E mutation analysis in circulating tumor cells

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis

Expression of eIF4E relevant biomarkers detected in circulating tumor cells from metastatic NSCLC and prostate cancer patients using antibody-independent ApoStream technology

Suchergebnisse filtern